Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149725 | 0.93 | RAB9A (0.52) | RAB9ANPC1MAPTTP53ALOX15 | |
| SCHEMBL5153406 | 0.90 | MAPT (0.47) | RAB9ANPC1MAPTITGA4MEN1 | |
| SCHEMBL5152922 | 0.90 | EPHX2 (0.50) | RAB9ANPC1TP53MEN1KMT2A | |
| SCHEMBL6210735 | 0.90 | ITGA4 (0.50) | RAB9ANPC1MAPTITGA4L3MBTL1 | |
| SCHEMBL5150038 | 0.89 | P2RY1 (0.46) | RAB9ANPC1ITGA4THRBMEN1 | |
| SCHEMBL5155651 | 0.88 | P2RY1 (0.45) | RAB9ANPC1SMN1; SMN2ITGA4THRB | |
| SCHEMBL6208854 | 0.86 | ITGA4 (0.57) | SMN1; SMN2ITGA4 | |
| SCHEMBL6210969 | 0.85 | ITGA4 (0.58) | ITGA4 | |
| SCHEMBL6212266 | 0.85 | ITGA4 (0.58) | MAPTSMN1; SMN2ITGA4LMNAKMT2A | |
| SCHEMBL5151727 | 0.85 | ITGA4 (0.51) | MAPTITGA4L3MBTL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | RAB9A 1984/4885NPC1 3300/4885MAPT 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.